XNAS · Healthcare · Biotechnology
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | Q1 2026 | -0.25 | -0.18 | +28.00% | $0 | ✅ Beat | +1.30% | -6.62% | — |
| 2026-03-05 | Q4 2025 | -0.25 | -0.27 | -8.00% | $26,000 | ❌ Miss | +3.75% | +2.71% | -4.71% |
| 2025-11-06 |
| Q3 2025 |
| -0.28 |
| -0.21 |
| +25.00% |
| $5,000 |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-12 | Q2 2025 | -0.32 | -0.27 | +15.62% | $5,000 | ✅ Beat | +4.44% | +0.00% | +1.93% |
| 2025-02-27 | Q4 2024 | -0.34 | -0.33 | +2.94% | $5,000 | ✅ Beat | +3.58% | -12.93% | -22.12% |
| 2024-11-12 | Q3 2024 | -0.35 | -0.32 | +8.57% | $5,000 | ✅ Beat | +0.32% | -21.29% | -9.48% |
| 2024-05-09 | Q1 2024 | -0.37 | -0.34 | +8.11% | $5,000 | ✅ Beat | -6.48% | +15.29% | -18.91% |
| 2024-03-27 | Q4 2023 | -0.43 | -0.33 | +23.26% | $37,000 | ✅ Beat | — | — | — |
Showing last 8 quarters.